Références Scientifiques Consultez la littérature scientifique qui soutient nos cibles moléculaires et notre approche létale synthétique. juin 2023 Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results Timothy A. Yap, Elisa Fontana, Et Al. Nature Medicine mai 2023 Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel Dominik Glodzik, Pier Selenica, Et Al. The Journal of Molecular Diagnostics avril 2023 Characterization of CCNE1 amplifications and associated genomic features in ovarian and uterine cancers Sunantha Sethuraman, Dominik Glodzik, Et Al. AACR 2023 avril 2023 Investigating Wee1 and Myt1 combined inhibition as a potential cancer therapeutic strategy Sargun Sokhi, Joanne Hadfield, Et Al. AACR 2023 avril 2023 Tumor heterogeneity of CCNE1 copy number assessed by fluorescence in situ hybridization (FISH) in ovarian and uterine cancers Adam Petrone, Elia Aguado-Fraile, Et Al. AACR 2023 septembre 2022 Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ Monica Bubenik, Pavel Mader, Et Al. Journal of Medicinal Chemistry juillet 2022 Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306 Janek Szychowski, Robert Papp, Et Al. American Chemical Society juillet 2022 Guiding ATR and PARP inhibitor combinationswith chemogenomic screens Zimmermann M, Bernier C, Et Al. Cell Reports avril 2022 CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition Gallo D, Young JTF, Fourtounis J, et al. Nature février 2022 RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors Roulston A, Zimmermann M, Papp R, et al. Molecular Cancer Therapeutics 1234 Notre pipeline comprend plusieurs programmes de développement. Voir Notre Pipeline
